Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting
December 05, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
Company presents positive results of a pre-specified patient population in Study 403 examining the effects of CAPLYTA® (lumateperone) in patients experiencing a major depressive episode with anxious...
Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 15, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
November 02, 2023 07:30 ET
|
Intra-Cellular Therapies Inc.
Q3 2023 total revenues increased to $126.2 million, compared to $71.9 million in the same period in 2022 CAPLYTA Q3 2023 net product sales were $125.8 million, compared to $71.9 million for the...
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
October 31, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast
October 26, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features
September 11, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 05, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 04, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...